JUNZHENG(SH:601216)2020-04-29 16:00Financial Performance - Operating revenue rose by 45.80% to CNY 3,561,613,172.61 year-on-year[4] - Net profit attributable to shareholders decreased by 12.97% to CNY 629,146,567.91 compared to the same period last year[4] - Basic earnings per share decreased by 12.95% to CNY 0.0746[4] - The company reported a decrease in short-term borrowings from ¥1,133,552,000.00 to ¥325,000,000.00, a reduction of approximately 71%[22] - The company's net profit for Q1 2020 is not explicitly stated but can be inferred from the increase in total revenue and operating costs[30] - The net profit for Q1 2020 was ¥143,999,239.88, down 34.2% from ¥219,124,609.95 in Q1 2019[34] - The total profit for Q1 2020 was ¥152,471,865.33, a decrease of 35.4% from ¥235,910,006.65 in Q1 2019[33] Assets and Liabilities - Total assets increased by 27.39% to CNY 40,188,094,343.89 compared to the end of the previous year[4] - The total current assets reached ¥11,808,069,389.58, up from ¥3,822,429,254.78 at the end of 2019, indicating a growth of about 208%[21] - The total liabilities increased to ¥19,921,531,734.27 from ¥11,974,535,879.46, marking a rise of about 66%[23] - The company's total assets as of March 31, 2020, were ¥40,188,094,343.89, compared to ¥31,547,935,821.40 at the end of 2019, reflecting an increase of approximately 27%[24] - The company's total equity attributable to shareholders reached ¥19,616,840,795.46, compared to ¥18,924,126,854.32 at the end of 2019, showing an increase of approximately 4%[24] - Current liabilities reached approximately ¥3.74 billion, with accounts payable at ¥136.40 million and other payables at ¥3.22 billion[46] Cash Flow - Net cash flow from operating activities decreased by 58.30% to CNY 217,705,347.99[4] - Cash and cash equivalents increased significantly to ¥194,556,186.73 from ¥1,823,346.05 in the previous year, indicating improved liquidity[25] - Cash inflows from investment activities totaled approximately RMB 12.68 billion, compared to RMB 1.09 billion in Q1 2019, marking an increase of 1,063.5%[37] - The net cash flow from investment activities was RMB 9.92 billion, a turnaround from a negative cash flow of RMB 2.72 billion in Q1 2019[37] - Cash outflows from financing activities were RMB 4.36 billion, significantly higher than RMB 514.28 million in Q1 2019[37] - The net cash flow from financing activities was negative at RMB 3.02 billion, compared to a positive cash flow of RMB 2.35 billion in the same quarter last year[37] Shareholder Information - The number of shareholders at the end of the reporting period was 115,832[10] - The largest shareholder, Du Jiangtao, holds 2,695,680,000 shares, accounting for 31.95% of the total[10] - The second-largest shareholder, Wuhai Junzheng Technology Industry Co., Ltd., holds 1,806,566,400 shares, accounting for 21.41%[10] Operational Changes - The company plans to acquire 100% equity of ADCHIM SAS through a share exchange with Beijing Bohui Innovation Biotechnology Co., Ltd[16] - The company has signed a share subscription agreement with Bohui Innovation, indicating a strategic move to become a shareholder in the company[18] - The company adopted new revenue recognition standards starting January 1, 2020, impacting the financial statements[43] - The company has implemented new revenue and lease standards starting from 2020, with no retrospective adjustments required[47] Research and Development - Research and development expenses increased to ¥24,644,270.09 in Q1 2020, compared to ¥17,771,299.09 in Q1 2019, reflecting a growth of 38.7%[30] Other Financial Metrics - The company reported a non-operating loss of CNY 20,430,286.45 due to various factors[8] - Financial expenses increased by 27,505,104.08 RMB, a growth rate of 34.08%, primarily due to increased exchange losses[15] - The company reported a decrease in investment income to ¥96,818,206.45 in Q1 2020 from ¥124,012,184.48 in Q1 2019[33] - The company incurred financial expenses of ¥26,617,456.39 in Q1 2020, significantly higher than ¥2,263,173.18 in Q1 2019[33]